Is this message not displayed correctly? Please click here for the online version.
|
|
Dear , Welcome to the latest issue of the HealthCapital newsletter,
What was once considered a black box is rapidly becoming intelligible: contemporary neuroscience reveals how we think, learn, decide, and regulate emotions – unlocking new pathways for prevention, therapy, AI, and innovative work environments.
The German capital region Berlin-Brandenburg continues to gain momentum in this field. This is particularly evident in the renewal of the Einstein Professorship for Prof. Surjo Soekadar, which will enable the establishment of a NeuroTech Open Innovation Hub at Charité. The goal here is to bring clinical neurotechnology into patient care more quickly, such as modern brain-computer interfaces for people with motor or cognitive impairments. You can learn more about these developments in our interview with Prof. Soekadar.
At the same time, Berlin’s research ecosystem demonstrates an extraordinary breadth of topics and scientific depth. At the Berlin Institute of Health, Johanna Quandt-Professor Petra Ritter is working to improve diagnostics and therapy for diseases such as Alzheimer’s, stroke, and epilepsy with the help of brain simulations.
The new OPM-MEG Center at Charité and the Physikalisch-Technische Bundesanstalt opens up new possibilities for a more precise understanding of psychiatric and neurological disorders. The NeuroCure Cluster of Excellence has been conducting interdisciplinary research into the fundamentals of neurological and psychiatric disorders for many years and enjoys international appeal. And with the EU project NerveRepack, Fraunhofer IZM is advancing new neurotechnological solutions for people with amputated or paralyzed limbs.
Our companies are also making a strong impact. The startup Nuuron is developing a fully digital Alzheimer’s therapy based on neuromodulatory technologies and has secured significant investments for this purpose. At the same time, eemagine, a long-established Berlin-based company, is a global leader in EEG and neuronavigation systems.
Recent developments clearly show that neuroscience is one of the key innovation fields of the future—and Berlin-Brandenburg is among its most important hubs. Research, clinical application, and economic dynamism are closely intertwined here, creating an ecosystem that sets international standards.
Your Dr. Kai Bindseil Berlin Partner for Business and Technology |
|
Interview | Aleksandar Ivanovski Aleksandar Ivanovski is a senior machine learning engineer at Recare, a Berlin-based company that has been developing digital discharge management for hospitals since 2017 and now connects more than 700 acute care clinics. With his book “Beyond the Hype: A Practical Guide to AI Implementation for Business Leaders” (July 2025), he addresses decision-makers who not only want to understand AI, but also want to put it to practical use. |
|
|
At the Brain-Computer-Interface – NeuroTech for Therapy and Diagnostics in Berlin Neurotechnology currently is one of the most exciting areas of innovation at the intersection between medicine, digitalization and engineering. What still sounded like science fiction a mere couple of years ago has long since become reality in the capital region, where the NeuroTech segment is growing dynamically. Applications range from innovative diagnostic methods to new therapeutic approaches that enable better care for neurological conditions. Research in this area is gaining further significance since demographic change is leading to a growing number of patients affected by neurogenerative diseases – a trend that stakeholders in the capital region recognized early on. |
|
|
Interview | Prof. Surjo Soekadar Prof. Surjo Soekadar is the head of the research division Translation and Neurotechnology at Charité - Universitätsmedizin Berlin and is regarded as a leading authority in the field of clinical neurotechnology. Last year, he received a grant for his research from the Einstein Foundation Berlin for the second time. His current Einstein Professorship is partially dedicated to the establishment of a NeuroTech Open Innovation Hub that enables start-ups and young teams of founders to validate their concepts. The hub is to be closely integrated with the newly founded ARC Innovation Center and the Berlin Institute of Health at Charité – Universitätsmedizin Berlin. We talked to Prof. Soekadar about the hub, the ARC and the arising opportunities. |
|
|
Interview | The Einstein Center Digital Future The Einstein Center Digital Future, known as the ECDF, is a Berlin-based centre for digitalisation research. It stands for independent, interdisciplinary research into the shaping and critical reflection of digital transformation, developed in partnership with businesses, policymakers and civil society. Its unique public-private partnership model brings together over 30 partners and has been enriching Brain City Berlin since 2017. |
|
|
bio:cap – New Investival for Life Sciences and AI in Berlin In Berlin, a new international event brings life sciences, artificial intelligence and investors together. From June 9 through 11 of 2026, bio:cap, a combination of investment forum, innovation platform and networking festival, takes place at Messe Berlin for the first time. The life sciences and AI festival aims to forge effective contacts between start-ups, research institutions, investors, established enterprises and political decision makers.
|
|
|
The tip from our relocation experts Why You Should Follow the “Invest in Berlin” LinkedIn ChannelLooking for insights into where smart investment opportunities emerge? The LinkedIn focus channel “ Invest in Berlin” delivers exactly the content that matters to investors and growth‑driven companies. |
|
|
You’ll gain first‑hand insights into Berlin’s most dynamic sectors – from AI, deep tech, and fintech to health, games, and creative industries. The channel brings together the latest funding and incentive news, expansion projects, market insights, and real success stories that explain why Berlin continues to attract international capital. Beyond market information, Invest in Berlin offers a window into the city’s ecosystem and shows how companies are actively supported in their market entry and growth journey – through location services, strong network connections, and guidance on incentives and expansion. In short: If you want to understand Berlin as an investment destination, spot opportunities early, and stay close to the pulse of one of Europe’s most exciting markets, this channel is a must‑follow. Susann Kaffenberger Manager Biotech | Pharma Berlin Partner for Business and Technology CONTACT US!
|
|
|
|
|
International Conference on Nuclear Cardiology (ICNC)
May 17-19, 2026 | Berlin, Germany
Read more |
|
GeneNovate Investors' Day
June 9, 2026 | Berlin, Germany
Read more |
|
TEF-Health Event – Advancing Trusted AI in Healthcare
June 9, 2026 | Berlin, Germany
Read more |
|
bio:cap International Life Science and AI Investival
June 9-11, 2026 | Berlin, Germany
Read more |
|
HLTH Europe 2026
June 15-18, 2026 | Amsterdam, Netherlands
Read more |
|
BIO International Convention 2026
June 22-25, 2026 | San Diego, USA
Read more |
|
Smart Health Asia 2026
July 1-2, 2026 | Singapore
Read more |
|
Save the Date – Opening Symposium BeCAT 2026
September 30, 2026 | Berlin, Germany
Read more |
|
For more events in the life science region Berlin-Brandenburg click here.
|
|
German Start-Up Remi Health Raises €5m to Scale Diagnostics-as-a-Service Platform Across Europe Remi Health, the Diagnostics-as-a-Service platform, today announced it has secured an oversubscribed €3 million seed round, bringing total funding to €5 million. The round was led by IBB Ventures, with participation from Catalpa Ventures, MSD Global Health Innovation Fund and existing pre-seed business angels. |
|
|
Dynamic42 and EPO Close the Gap in Brain Cancer Research One of the key challenges in brain cancer research is the limited availability of preclinical models. Dynamic42 GmbH, based in Jena, Germany, and EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH are addressing this gap through a new strategic collaboration that brings organ-on-chip technologies closer to the core of preclinical drug development.
|
|
|
A New Future Site for Berlin: The Health Innovation Quarter in Mitte At the heart of Brain City Berlin, a new Future Site is taking shape: the Health Innovation Quarter Berlin-Mitte. Here, science, industry and startups are working together on the health innovations of the future. The initiative was founded by Charité and the company Bayer, who are jointly creating a powerful innovation network that enriches the capital.
|
|
|
Cellbricks Therapeutics Raises €10 Million New Capital to Move Living Tissue Implants Toward the Clini
Read more |
|
Kupando Secures Additional €10 Million in Series A Financing to Advance Novel Immuno-Oncology and Infectious Diseases Programs
Read more |
|
Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
Read more |
|
Alexandra Knauer Receives the Pittcon Heritage Award
Read more |
|
European Microphysiological Systems Companies Launch World’s First Industry Association
Read more |
|
Gilead Acquires FMP and LMU Spin-Off Tubulis and Expands Oncology Pipeline with Next-Generation ADC
Read more |
|
Science and Technology News
|
|
|
BeCAT and Si-M: two new Berlin-based research facilities advancing personalized medicine On April, 22th, the BeCAT and Si-M were inaugurated in Berlin – two important beacons for our region. What they share is the goal of developing effective personalized therapies for diseases that have so far been considered incurable.
|
|
|
Chaos in Lymph Node Promotes Cancer In aggressive lymphomas, inflammatory messengers reprogram the “conductors” of the immune system, causing lymph node structure to collapse. A team led by Simon Haas describes in “Nature Cancer” this process for the first time using single-cell and spatial analyses.
|
|
|
A Fundamentally New Therapeutic Approach to Cystic Fibrosis: Nanobody Repairs Cellular Defect A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly into human cells and can repair the chloride channel most commonly affected in cystic fibrosis. The innovative therapeutic approach was developed in collaboration between teams from Charité – Universitätsmedizin Berlin and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP). The results have now been published in the journal Nature Chemical Biology.
|
|
|
New Study on Obesity Criteria Shows: Vast Majority of Affected Individuals Are Classified as Clinically Obese
Read more |
|
First “Protein Map” of Neurons That Initiate Pain
Read more |
|
Launch of the Einstein Center for Early Disease Interception
Read more |
|
Nutrient Timing Influences Gene Activity in Adipose Tissue
Read more |
|
Berlin University Alliance Secures Continued Funding in Excellence Strategy – a First for a University Consortium
Read more |
|
Gut Microbes Affect the Heart via the Brain
Read more |
|
New Protein Discovered as Key to Muscle Formation: PICALM Responds to Training and Fasting
Read more |
|
For more news from the cluster healthcare industries click here.
|
|
EDITOR | IMPRINT
This newsletter is operated by the cluster healthcare industries
Berlin-Brandenburg HealthCapital. Berlin Partner for Business and TechnologyFasanenstrasse 85 | 10623 Berlin | GermanyPhone: +49 30 46302-463Email: healthcapital (at) berlin-partner (dot) de Commercial Registry Entry Entered in the commercial registry of the Charlottenburg District Court, Registration number: HRB 13072 B VAT ID: DE 136629780 CEO: Dr. Stefan Franzke Chairman of the Supervisory Board: Carsten Jung
Editorial: In cooperation with dpa-Custom Content. Responsible body in terms of German Press LawCarolin Meltendorf, Press Spokeswoman Berlin Partner for Business and Technology© 2026 Berlin Partner for Business and Technology |
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe? Please click here.You want to unsubscribe from the newsletter (to: unknown@noemail.com)? Please click here.
|
|
|
|
|